Olmutinib
Olmutinib (HM61713; BI-1482694) is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib is used for NSCLC[1][2].
Product Specifications
CAS Number
1353550-13-6
Product Name Alternative
HM61713; BI 1482694
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Olmutinib.html
Purity
99.88
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC=CC(OC2=C3C(C=CS3)=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=N2)=C1)=O
Molecular Formula
C26H26N6O2S
Molecular Weight
486.59
Precautions
H302, H315, H319, H335
References & Citations
[1]Kim ES, et al. Olmutinib: First Global Approval. Drugs. 2016 Jul;76 (11) :1153-7.|[2]Mohamed W. Attwa, et al. Detection and characterization of olmutinib reactive metabolites by LC‐MS/MS: Elucidation of bioactivation pathways. Journal of Separation science. 18 November 2019.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
